TSX Exchange Symbol: RVX
CALGARY, Oct. 3, 2013 /PRNewswire/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual and special meeting of shareholders held on October 3, 2013, each of the six nominees proposed as a director and listed in its management information circular dated August 21, 2013 (the "Information Circular") were elected as directors. Proxy voting results for each nominee are set out below.
|Votes For||Votes Withheld||% For||% Withheld|
|Donald J McCaffrey||32,555,972||142,114||99.57%||0.43%|
At the meeting, shareholders were also asked to consider a resolution to approve anti-dilution adjustment provisions contained in certain outstanding common share purchase warrants of the Corporation, as more particularly described in the Information Circular. The warrant adjustment resolution failed to obtain approval from shareholders.
Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
|Donald J. McCaffrey||Kenneth Lebioda|
|President and CEO||SVP Business & Corporate Development|
|Resverlogix Corp.||Resverlogix Corp.|
|Phone: 403-254-9252||Phone: 403-254-9252|
|Email: email@example.com||Email: firstname.lastname@example.org|
SOURCE Resverlogix Corp.